Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain. …
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech -
Nanosonics achieves key FDA clearance as CORIS Endoscope coverage expands
March 9, 2026 - - Australian Biotech -
BPDInsights.ai has arrived as a new way to access knowledge
March 9, 2026 - - Latest News -
How to Use BPDInsights.ai - to learn and to train the platform
March 9, 2026 - - Latest News -
Life sciences leaders gather in Sydney to advance women’s leadership on International Women’s Day
March 5, 2026 - - Latest News